We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 24

Those drugs cost how much?? Chemist warehouse price list misleading but not for the reasons you might think

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • October 29 2012

Last Monday the Supreme Court of Queensland held that a price list published by various Chemist Warehouse pharmacies in Cairns, Nerang, Coolangatta and other parts of Queensland was likely to mislead or deceive and therefore contravene clause 18 of the Australian Consumer Law (Competition and Consumer Act 2010 (Cth), schedule 2, section 18

Vioxx class action: special leave refused

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • July 10 2012

On 15 May 2012 the High Court refused special leave to appeal from the decision of the Full Federal Court to refuse to award damages in the Vioxx class action

Federal Court prescribes hard medicine for Vioxx class action

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 15 2012

The full court of the Federal Court of Australia recently overturned a damages award in the VIOXX class action, confirming once again that issues of causation are no less difficult to prove in large-scale class actions than in individual proceedings

Pharmaceuticals - copyright in PIs and indirect patent infringement

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • August 4 2011

In the recent decision in Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3), Justice Jagot of the Federal Court found liability for indirect patent infringement in the context of supply of a pharmaceutical product

Competition regulators continue their campaign against pharmaceutical companies

  • King & Wood Mallesons
  • -
  • Australia, USA
  • -
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year

European Commission ups the cost of paying for delay

  • King & Wood Mallesons
  • -
  • Australia, European Union, USA
  • -
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

ACCC joins NRM to Advanced Medical Institute proceedings, alleging unfair contract terms

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • November 3 2011

On 7 September 2011, the ACCC announced that the Federal Court had granted orders to add NRM Corporation Pty Ltd and NRM Trading Pty Ltd as respondents in the ACCC’s existing case against Advanced Medical Institute for alleged unconscionable conduct

Australian court decides important gene patenting question isolated genetic material patentable subject matter

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • February 15 2013

Earlier today, the Federal Court rejected a claim brought by Cancer Voices Australia that isolated genetic material (DNA or RNA) that is naturally

It's all in the definition - "drug" or "pharmaceutical item"

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • May 19 2011

AstraZeneca has been unsuccessful in its attempt to overturn a decision of the Minister for Health and Ageing to include a particular dose of rosuvastatin (sold as Crestor, to lower cholesterol) in the Statins-HP "therapeutic group" on the Pharmaceutical Benefits Scheme ("PBS"

European Court of Justice says no to patents requiring the destruction of a human embryo - an Australian perspective

  • King & Wood Mallesons
  • -
  • Australia, European Union
  • -
  • October 20 2011

Article 6(2)(c) of the European Biotech Directive excludes inventions which use human embryos for industrial or commercial purposes from patentability